{"filing":{"accession_number":"0001104659-26-078009","cik":"0001737953","ticker":"REPL","company_name":"Replimune Group, Inc.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"tm2619037d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926078009/tm2619037d1_8k.htm"},"events":[{"id":14118,"run_id":12556,"accession_number":"0001104659-26-078009","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces FDA acceptance of a Biologics License Application (BLA) resubmission for RP1 in advanced melanoma with an expedited review timeline (decision expected by August 2, 2026) and an advisory committee meeting planned. This is a material regulatory milestone for a clinical-stage biotech company's lead product candidate, but it does not fit the specific event types of earnings release, M\u0026A activity, impairment, or other defined categories. It is clearly operational/strategic in nature—a significant product development and regulatory advancement event.","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11460,"accession_number":"0001104659-26-078009","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA acceptance of a Biologics License Application (BLA) resubmission for RP1 in advanced melanoma with an expedited review timeline (decision expected by August 2, 2026) and an advisory committee meeting planned. This is a material regulatory milestone for a clinical-stage biotech company's lead product candidate, but it does not fit the specific event types of earnings release, M\u0026A activity, impairment, or other defined categories. It is clearly operational/strategic in nature—a significant product development and regulatory advancement event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:15:37.882043+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11460,"accession_number":"0001104659-26-078009","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA acceptance of a Biologics License Application (BLA) resubmission for RP1 in advanced melanoma with an expedited review timeline (decision expected by August 2, 2026) and an advisory committee meeting planned. This is a material regulatory milestone for a clinical-stage biotech company's lead product candidate, but it does not fit the specific event types of earnings release, M\u0026A activity, impairment, or other defined categories. It is clearly operational/strategic in nature—a significant product development and regulatory advancement event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:15:37.882043+00:00","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-06-26"}]}